2.80
-0.05 (-1.75%)
Penutupan Terdahulu | 2.85 |
Buka | 2.76 |
Jumlah Dagangan | 28,995 |
Purata Dagangan (3B) | 628,724 |
Modal Pasaran | 4,904,718 |
Harga / Jualan (P/S) | 0.530 |
Harga / Buku (P/B) | 0.610 |
Julat 52 Minggu |
Margin Keuntungan | -16.81% |
Margin Operasi (TTM) | -26.79% |
EPS Cair (TTM) | -0.900 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 11.00% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 2.74% |
Nisbah Semasa (MRQ) | 3.81 |
Aliran Tunai Operasi (OCF TTM) | -2.23 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -1.91 M |
Pulangan Atas Aset (ROA TTM) | -10.86% |
Pulangan Atas Ekuiti (ROE TTM) | -17.78% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Specialty Chemicals (US) | Menurun | Menurun |
Specialty Chemicals (Global) | Menurun | Menurun | |
Stok | BioNexus Gene Lab Corp | - | - |
AISkor Stockmoo
Konsensus Penganalisis | -2.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 0.5 |
Purata Bergerak Teknikal | 1.5 |
Osilator Teknikal | 0.5 |
Purata | 0.13 |
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases. |
|
Sektor | Basic Materials |
Industri | Specialty Chemicals |
Gaya Pelaburan | Small Value |
% Dimiliki oleh Orang Dalam | 49.09% |
% Dimiliki oleh Institusi | 0.99% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
30 Apr 2025 | Pengumuman | BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness |
15 Apr 2025 | Pengumuman | BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory |
07 Mar 2025 | Pengumuman | BioNexus Gene Lab Corp and ML Tech Partner to Enhance Ethereum-focused Treasury Strategy |
05 Mar 2025 | Pengumuman | BioNexus Gene Lab Corp. Announces Board Approval of Ethereum Treasury Strategy and Release of Strategic Whitepaper |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |